Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2021-08, Vol.144, p.155585-155585, Article 155585
• Main Authors: Saraç Öztürk, Gonca, Ergun, Tülin, Peker Eyüboğlu, İrem, Akkiprik, Mustafa
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; C-Reactive Protein - metabolism; Cytokines - blood; Female; Hidradenitis suppurativa; Hidradenitis Suppurativa - blood; Hidradenitis Suppurativa - metabolism; hs-CRP; Humans; IL-17A; IL-1β; IL-23; Inflammation - blood; Interleukin-17 - blood; Interleukin-1beta - blood; Interleukin-23 - blood; Male; Middle Aged; Skin - metabolism; TNF-α; Tumor Necrosis Factor-alpha - blood; Young Adult
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2021.155585

•Inflammation is now considered as the main driver for hidradenitis suppurativa (HS).•Treatment results with inhibitors of TNF, IL-17, IL-23 and IL-1 are promising.•There is no serum marker for HS that indicates severity or response to treatment yet.•We found no significant change in serum TNF-α, IL-1β, IL-17A and IL-23 in HS patients.•Serum hs-CRP may be a marker for HS, as it significantly decreased with treatment. Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease that leads to scar formation. The immune pathogenesis of HS is not fully understood and inhibitors of tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-1, IL-23 can be used for treating HS. Identification of serum biomarkers may help understanding individual differences in HS pathogenesis, evaluating disease severity and developing more effective treatment methods. To assess the serum levels of proinflammatory cytokines TNF-α, IL-1β, IL-17A, IL-23 and high-sensitivity C-reactive protein (hs-CRP) in patients with HS and to evaluate the impact of treatment on cytokine levels. Serum proinflammatory cytokine and hs-CRP levels were measured using enzyme-linked immunosorbent assay kits in 24 healthy controls and in 26 HS patients at baseline and after a 3-month treatment. Patients were treated with clindamycin, adalimumab, dapsone, doxycycline and acitretin, based on HS condition and laboratory results. Control, pre-treatment and post-treatment values were compared. HS patients had significantly higher hs-CRP levels than controls which decreased following treatment (p = 0,010, p = 0,007). No significant difference was found in serum levels of TNF-α, IL-1β, IL-17A, IL-23 compared to controls and post-treatment levels. There is insufficient data to suggest TNF-α, IL-1β, IL-17A and IL-23 as serum biomarkers in HS. hs-CRP can be used as an indicator of treatment response and systemic inflammation.